MPPE1 and neoplasm: In summary, even though other DC types can be successfully harnessed for cancer vaccines in mouse preclinical models, many studies showed that in vivo targeting of cDC1 is highly efficient for the activation of antitumor CTL responses able to induce complete tumor rejection in prophylactic settings and to delay significantly tumor progression or metastasis in therapeutic settings (Table S1).